Lonza

Update in progress

LONN.SW (Swiss)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Lonza Group AG and its subsidiaries supply pharma, biotech and nutrition products and services worldwide. It operates four segments: Biologics, for contract development and manufacturing of drug substances and products; Small Molecules, offering integrated development and manufacturing for drug substances and intermediates; Cell & Gene, developing platforms and providing CDMOs, regulatory support, and cell therapies; Capsules & Health Ingredients, providing capsules, dosage forms and health ingredients.

Company score

Sentiment: 1.35; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.41; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.67; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.47; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.44; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.89; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive